Aspira Pathlab & Diagnostics (BOM:540788) NonCurrent Deferred Liabilities: ₹0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540788 Aspira Pathlab & Diagnostics Ltd BOM:540788
51 GF Score
Price ₹91.50
GF Value ₹74.02
Valuation Modestly Overvalued
View Full Analysis

What is Aspira Pathlab & Diagnostics NonCurrent Deferred Liabilities?

Aspira Pathlab & Diagnostics BOM:540788 +1.95% 51 NonCurrent Deferred Liabilities is ₹0.0 Mil as of Jun. 2026. GuruFocus rates BOM:540788 with a GF Score™ of 51/100 and a GF Value™ of ₹74.02 (Modestly Overvalued).

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Aspira Pathlab & Diagnostics's non-current deferred liabilities for the quarter that ended in Jun. 2026 was ₹0.0 Mil.

Aspira Pathlab & Diagnostics NonCurrent Deferred Liabilities Related Terms

Aspira Pathlab & Diagnostics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Aspira Pathlab & Diagnostics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Pathlab & Diagnostics NonCurrent Deferred Liabilities Chart

Aspira Pathlab & Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Aspira Pathlab & Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:540788
51GF Score
Aspira Pathlab & Diagnostics Ltd BOM:540788
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of ₹0.0 Mil mean?
Aspira Pathlab & Diagnostics (BOM:540788) has a NonCurrent Deferred Liabilities of ₹0.0 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Aspira Pathlab & Diagnostics and its competitors.
Is Aspira Pathlab & Diagnostics' NonCurrent Deferred Liabilities too high?
Aspira Pathlab & Diagnostics' current NonCurrent Deferred Liabilities is ₹0.0 Mil. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' NonCurrent Deferred Liabilities compare to TMO and DHR?
Aspira Pathlab & Diagnostics' NonCurrent Deferred Liabilities of ₹0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Liabilities depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Aspira Pathlab & Diagnostics and its competitors. Aspira Pathlab & Diagnostics's current NonCurrent Deferred Liabilities is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹74.02, compared to a current price of ₹91.50 — trading 23.6% above its estimated fair value. The current NonCurrent Deferred Liabilities is ₹0.0 Mil. Aspira Pathlab & Diagnostics' overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current NonCurrent Deferred Liabilities is ₹0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued. The current stock price of ₹91.50 is trading 23.6% above its estimated GF Value™ of ₹74.02. GuruFocus considers Aspira Pathlab & Diagnostics to be Modestly Overvalued.

Key valuation signals for BOM:540788:

  • NonCurrent Deferred Liabilities: ₹0.0 Mil
  • GF Value™: ₹74.02 vs. price of ₹91.50 (23.6% above fair value)
  • GF Score™: 51/100

No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Pathlab & Diagnostics Business Description

Address 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (west), Mumbai, MH, IND, 400086
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
51GF Score

Get the complete analysis for BOM:540788

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹91.50
Price
₹74.02
GF Value